Trends in Uveal Melanoma Presentation and Survival During Five Decades: A Nationwide Survey of 3898 Swedish Patients.
Sweden
cancer
melanoma
ophthalmology (MeSH)
survival
time-trend
treatment
uveal melanoma
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
04
2022
accepted:
17
05
2022
entrez:
20
6
2022
pubmed:
21
6
2022
medline:
21
6
2022
Statut:
epublish
Résumé
In contrast to most other cancers, uveal melanoma (UM) is characterized by an absence of major improvements in patient survival during the last several decades. In this study, we examine changes in incidence rates, patient age and tumor size at diagnosis, treatment practices and survival for patients diagnosed in Sweden during the period 1960-2010. All patients diagnosed with posterior UM between January 1st, 1960, and December 31st, 2009, in Sweden, were included ( Crude (6.5-11.6 cases/million/year) and age-standardized incidence rates (5.6-9.6 cases/million/year) varied between individual years during the study period, but both had a stable linear trend overall ( In the period from 1960-2010, crude and age-standardized incidence rates of UM have remained stable in Sweden. Several other aspects have changed: Plaque brachytherapy with ruthenium-106 has replaced enucleation as the most common primary treatment modality; patients have become older and their tumors smaller at the time of diagnosis; and their survival has improved. This might indicate a beneficial survival effect of earlier diagnosis and treatment, but the potential influence from lead-time bias should be taken into consideration.
Sections du résumé
Background
UNASSIGNED
In contrast to most other cancers, uveal melanoma (UM) is characterized by an absence of major improvements in patient survival during the last several decades. In this study, we examine changes in incidence rates, patient age and tumor size at diagnosis, treatment practices and survival for patients diagnosed in Sweden during the period 1960-2010.
Methods
UNASSIGNED
All patients diagnosed with posterior UM between January 1st, 1960, and December 31st, 2009, in Sweden, were included (
Results
UNASSIGNED
Crude (6.5-11.6 cases/million/year) and age-standardized incidence rates (5.6-9.6 cases/million/year) varied between individual years during the study period, but both had a stable linear trend overall (
Conclusion
UNASSIGNED
In the period from 1960-2010, crude and age-standardized incidence rates of UM have remained stable in Sweden. Several other aspects have changed: Plaque brachytherapy with ruthenium-106 has replaced enucleation as the most common primary treatment modality; patients have become older and their tumors smaller at the time of diagnosis; and their survival has improved. This might indicate a beneficial survival effect of earlier diagnosis and treatment, but the potential influence from lead-time bias should be taken into consideration.
Identifiants
pubmed: 35721086
doi: 10.3389/fmed.2022.926034
pmc: PMC9200980
doi:
Types de publication
Journal Article
Langues
eng
Pagination
926034Informations de copyright
Copyright © 2022 Gill, Herrspiegel, Sabazade, Fili, Bergman, Damato, Seregard and Stålhammar.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Med. 2019 Jun;8(6):2784-2792
pubmed: 30993893
Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1008-11
pubmed: 12601021
Br J Ophthalmol. 2020 Jan;104(1):26-32
pubmed: 30910871
Br J Cancer. 2012 Mar 13;106(6):1171-6
pubmed: 22353812
Sci Rep. 2021 Apr 26;11(1):8923
pubmed: 33903674
Melanoma Res. 2019 Dec;29(6):561-568
pubmed: 30664106
Ophthalmology. 2003 May;110(5):962-5
pubmed: 12750098
JAMA Ophthalmol. 2014 May;132(5):605-13
pubmed: 24626610
Br J Ophthalmol. 2022 Apr;106(4):510-517
pubmed: 33452185
JAMA Ophthalmol. 2015 Apr;133(4):376-83
pubmed: 25555246
Arch Ophthalmol. 2009 Aug;127(8):989-98
pubmed: 19667335
Ocul Oncol Pathol. 2018 Apr;4(3):145-151
pubmed: 29765944
Prog Retin Eye Res. 2018 Sep;66:187-199
pubmed: 29571968
Br J Ophthalmol. 2021 Apr;105(4):582-586
pubmed: 32522791
Curr Oncol Rep. 2017 Jul;19(7):45
pubmed: 28508938
Commun Med (Lond). 2022 Mar 1;2:18
pubmed: 35603296
BMC Cancer. 2021 Nov 24;21(1):1270
pubmed: 34819035
Ophthalmology. 2000 Aug;107(8):1443-9
pubmed: 10919885
Crit Rev Oncol Hematol. 2022 Apr;172:103652
pubmed: 35304261
N Engl J Med. 2021 Sep 23;385(13):1196-1206
pubmed: 34551229
Ann Oncol. 2019 Aug 1;30(8):1370-1380
pubmed: 31150059
Am J Ophthalmol. 2019 Jun;202:100-108
pubmed: 30772347
Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3282-7
pubmed: 12882771
Ocul Oncol Pathol. 2021 Mar;7(2):133-141
pubmed: 33981696
Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2579-83
pubmed: 12147588
Ophthalmology. 2001 May;108(5):829-31
pubmed: 11319992
Ocul Oncol Pathol. 2019 Oct;5(6):432-439
pubmed: 31768367
Br J Cancer. 2010 Jul 27;103(3):285-90
pubmed: 20661247
Acta Ophthalmol. 2021 Dec;99(8):e1474-e1482
pubmed: 33738986
Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4651-9
pubmed: 14578381
Sci Rep. 2020 Jul 9;10(1):11297
pubmed: 32647177
Exp Eye Res. 2019 May;182:175-181
pubmed: 30954503
Cancer Epidemiol. 2017 Feb;46:50-56
pubmed: 28027488
Nat Commun. 2018 Jan 9;9(1):116
pubmed: 29317634
JAMA Ophthalmol. 2015 Aug;133(8):881-7
pubmed: 25974357
Ophthalmic Epidemiol. 2006 Apr;13(2):85-96
pubmed: 16581612
Bone Marrow Transplant. 2007 Aug;40(4):381-7
pubmed: 17563735
Acta Ophthalmol. 2018 Aug;96(5):510-518
pubmed: 29338132
Eur J Ophthalmol. 2013 Mar-Apr;23(2):208-16
pubmed: 23065853
Br J Ophthalmol. 2014 Oct;98(10):1349-54
pubmed: 24825846
Retina. 2012 Jul;32(7):1363-72
pubmed: 22466491
Cancer Treat Rev. 2017 Nov;60:44-52
pubmed: 28881222
Ophthalmology. 2011 Sep;118(9):1881-5
pubmed: 21704381
Cancers (Basel). 2021 Mar 07;13(5):
pubmed: 33800007